Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.…
Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
Monopar Therapeutics (NASDAQ: MNPR) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 22 employees.
The shares were at 69.00 USD on 20 November 2026, down 14.8% over 52 weeks. Its 52-week range is 50.07 USD to 124.42 USD: the price is 44.5% below the high and 37.8% above the low.
Its market capitalisation is 467.60M USD.
Monopar Therapeutics reports return on equity of -10.0% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 129.09M USD. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. 12 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 130.17 USD is 88.6% above the current price. The next earnings report is expected on 18 March 2027.